USP9X and prostate carcinoma: Knockdown of NSD2 induced cell apoptosis and led to the enhancing sensitivity of osteosarcoma to cisplatin.210 WP1130, the USP9x inhibitor, induced the degradation of transcription factor PBX1 and accelerated cell apoptosis in prostate cancer, which provided a new idea for prostate cancer treatment.211